PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 7 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Shengdi Dahuang Decoction (containing 15g raw Rehmannia glutinosa and 5g raw rhubarb) was evaluated in a double-blind, placebo-controlled trial to improve 90-day functional outcomes, with preclinical data suggesting it reduces inflammatory injury in rats [PMID:40752894].
Catalpol from Rehmannia glutinosa improved renal anemia and fibrosis by targeting Nrf2 activation in NRK-52E cells and C57BL/6N male mice [PMID:39075978].
Raw Rehmannia Radix Polysaccharide (RRRP) reduced mortality by approximately 20.0% and alleviated liver pathological changes in vitro and in vivo [PMID:28638862].
Tangshen Recipe (containing raw rehmannia root) was studied for its effects on homocysteine metabolism in patients with diabetic nephropathy [PMID:21910334].
Evidence summary
PubMed sources
- 1.PMID: 25923413 (2015) — The Core Pattern Analysis on Chinese Herbal Medicine for Sjögren's syndrome: A Nationwide Population-Based Study. · Scientific reports
- 2.PMID: 27974236 (2017) — Integrative therapy decreases the risk of lupus nephritis in patients with systemic lupus erythematosus: A population-based retrospective cohort study. · Journal of ethnopharmacology
- 3.PMID: 39075978 (2024) — Catalpol from Rehmannia glutinosa Targets Nrf2/NF-κB Signaling Pathway to Improve Renal Anemia and Fibrosis. · The American journal of Chinese medicine
- 4.PMID: 40752894 (2026) — Treatment of acute intracerebral haemorrhage with a Chinese herbal formula (Shengdi Dahuang Decoction): a multicentre, double-blind, randomised, placebo-controlled trial. · Stroke and vascular neurology
- 5.PMID: 28638862